A [U-232]UBe13 neutron source was designed and modeled and the fluence and flux distributions were calculated. The [U-232]U decay chain emits six high energy alpha particles in quick succession and is ideal for use in a beryllium (a,n) neutron source. [U-232]U is an undesirable byproduct in the production of [U-233]U in the thorium fuel cycle; its concentrations can vary from 5-3000 ppm in bred [U-233]U. A 1.1018-cm diameter by 1.1018-cm tall cylinder of [U-233]UBe13 with 300ppm U-232 at 0.74 GBq (20 mCi) was modeled and found to have a peak yield of 3.5*105 n/s after 10.17 years. At this peak yield, the [U-232]UBe13 source has better neutron production efficiency per initial alpha emission activity than other beryllide neutron sources.

No description available.

No description available.

Ce travail décrit la synthèse et l’étude conformationnelle de nouveaux oligomères mixtes. Dans le premier chapitre, en exploitant des travaux antérieurs concernant la synthèse des N-aminodipeptides, nous avons obtenu des oligomères mixtes, alternant des liens amides et N-aminoamides nommés [[allpha]/[alpha]-N-amino]mères. L’oligomérisation des N-aminopeptides en phase liquide est réalisable grâce à un couplage au fluorure d’acide à partir d’une unité de base possédant les protections Boc (extrémité N-terminale), Bn (extrémité C-terminale) et phtaloyle (azote latéral). Le deuxième chapitre présente les résultats obtenus par différentes méthodes spectroscopiques (RMN, IR et DC) et modélisation moléculaire sur les différents oligomères synthétisés dans le chapitre 1. Ces travaux ont permis de mettre en évidence un repliement répétitif original par une liaison hydrogène de type C8 impliquant un groupement carbonyle du phtalimide et un proton amidique / This work describes the synthesis and the conformational study of new mixed oligomers. In the first chapter, using previous work on the synthesis of N-aminodipeptids, we were obtained mixed oligomers alternating amid and N-aminoamid bond named [[alpha]/[alpha]-N-amino]mers. The oligomerization of N-aminopeptids in liquid phase was achieved through an acid fluorid coupling from a building block with the protections Boc (N-terminus), Bn (C-terminus) and phtaloyl (N-side). The second chapter presents the results obtained by different conformational spectroscopic methods (NMR, IR and DC) and molecular modeling on the various oligomers synthesized in Chapter 1. This work has allowed to highlight a original repetitive folding by a C8 hydrogen bond involving the carbonyl group of phthalimid and a amid proton

Mucopolysaccharidosis (MPS) IIIB is an autosomal recessive disorder caused by a defect in alpha-N-acetylglucosaminidase (NAGLU), a lysosomal enzyme involved in the degradation of heparan sulphate. Dysfunctional NAGLU gives rise to a clinical phenotype of severe and progressive mental retardation, often accompanied by hyperactivity and aggressive behaviour. At present, there is no effective treatment for MPS IIIB. However, cloning of the human NAGLU cDNA has made the potential production of human recombinant enzyme for use in enzyme replacement therapy (ERT) a viable option. The work outlined herein focuses on attempts to produce human recombinant NAGLU (rNAGLU) using both yeast and insect cell based expression systems; with the major focus on yeast based expression. Use of a humanized yeast strain, codon optimisation of a portion of the NAGLU gene, selection of Mut+, MutS and multiple integrant strains, and growth at decreased temperature were explored to optimise NAGLU expression in the methylotrophic yeast, Pichia pastoris. As none of these measures resulted in abundant NAGLU production, Sf9 and Tni insect cell lines were investigated as an alternate expression system. Additionally, a protein transduction domain (PTD) was fused to NAGLU (NTAT) to circumvent current problems faced in delivering therapeutic enzymes to the brain. NAGLU protein, with and without a fused PTD, were expressed using stable transfection and baculovirus infection techniques. Small scale experiments utilizing the baculovirus expression vector system (BEVS) have yielded promising results, generating functionally active NAGLU and NTAT protein of the expected approximately 80-85 kDa molecular mass. This preliminary success indicates the BEVS may be an attractive option for the large scale production of rNAGLU and rNTAT.

Mucopolysaccharidosis (MPS) IIIB is an autosomal recessive disorder caused by a defect in alpha-N-acetylglucosaminidase (NAGLU), a lysosomal enzyme involved in the degradation of heparan sulphate. Dysfunctional NAGLU gives rise to a clinical phenotype of severe and progressive mental retardation, often accompanied by hyperactivity and aggressive behaviour. At present, there is no effective treatment for MPS IIIB. However, cloning of the human NAGLU cDNA has made the potential production of human recombinant enzyme for use in enzyme replacement therapy (ERT) a viable option. The work outlined herein focuses on attempts to produce human recombinant NAGLU (rNAGLU) using both yeast and insect cell based expression systems; with the major focus on yeast based expression. Use of a humanized yeast strain, codon optimisation of a portion of the NAGLU gene, selection of Mut+, MutS and multiple integrant strains, and growth at decreased temperature were explored to optimise NAGLU expression in the methylotrophic yeast, Pichia pastoris. As none of these measures resulted in abundant NAGLU production, Sf9 and Tni insect cell lines were investigated as an alternate expression system. Additionally, a protein transduction domain (PTD) was fused to NAGLU (NTAT) to circumvent current problems faced in delivering therapeutic enzymes to the brain. NAGLU protein, with and without a fused PTD, were expressed using stable transfection and baculovirus infection techniques. Small scale experiments utilizing the baculovirus expression vector system (BEVS) have yielded promising results, generating functionally active NAGLU and NTAT protein of the expected approximately 80-85 kDa molecular mass. This preliminary success indicates the BEVS may be an attractive option for the large scale production of rNAGLU and rNTAT.

The aim of the work described in this thesis was to explore the synthesis of glycosidase inhibitors and to evaluate their potential as anti-cancer agents. Glycosidases catalyze the fission of glycosidic bonds and are involved in vital biological functions. With regard to their potential for anti-cancer therapy, two glycosidases were identified: α-N-acetyl-galactosaminidase and β-N-acetyl-hexosaminidase. The former has been implicated in causing immunosuppression in advanced cancer patients by negating the effect of the macrophage activating factor (MAF), while the latter is secreted by invading cancer cells and hence associated with metastasis formation. The synthetic focus was on generating piperidine and azetidine iminosugars, carbohydrate mimetics with their endocylic oxygen replaced by nitrogen. Their structural similarity to carbohydrates make iminosugars excellent inhibitors of glycosidases. Following synthesis of a pipecolic amide, its previously reported potent β-N-acetyl-hexosaminidase inhibition was confirmed. This data, along with inhibition profiles of several pyrrolidines, allowed the generation of a molecular model for predicting activity of β-N-acetyl-hexosaminidase inhibitors. The model was used to select azetidines in the D/L-ribo and D-lyxo configuration as suitable candidates to be explored in novel chemical space, leading to the first synthesis of a fully unprotected 3-hydroxy-2-carboxy-azetidine. The potent α-N-acetyl-galactosamindase inhibitor 2-acetamido-1,2-dideoxy-D-galacto-nojirimycin (DGJNAc) was successfully derivatised via N-alkylation. Important structural discoveries with regard to glycosylation of vitamin D₃-binding protein, the precursor of MAF, were made using MALDI mass-spectrometry. By comparing the enzymatic and cellular inhibition of N-alkylated derivatives of DGJNAc and a pyrrolidine the following generalization on iminosugar biodistribution was found: N-butylation promotes uptake into the cell/organelles, while hydrophilic side-chains restrict cellular access. An in vitro assay evaluating cancer cell invasion was devised and β-N-acetyl-hexoamindase inhibitors were shown to retard cell migration, including with the highly metastatic breast cancer cell line MDA-MB-231. Additive effects where found when the iminosugar was combined with a protease inhibitor, suggesting potential for future combination therapy.